Fintel reports that on October 17, 2025, UBS maintained coverage of Quest Diagnostics (NYSE:DGX) with a Neutral recommendation.
Analyst Price Forecast Suggests 2.45% Upside
As of September 30, 2025, the average one-year price target for Quest Diagnostics is $191.40/share. The forecasts range from a low of $171.03 to a high of $210.00. The average price target represents an increase of 2.45% from its latest reported closing price of $186.82 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Quest Diagnostics is 9,894MM, a decrease of 5.97%. The projected annual non-GAAP EPS is 8.85.
What is the Fund Sentiment?
There are 1,783 funds or institutions reporting positions in Quest Diagnostics. This is an increase of 50 owner(s) or 2.89% in the last quarter. Average portfolio weight of all funds dedicated to DGX is 0.23%, an increase of 3.83%. Total shares owned by institutions increased in the last three months by 4.71% to 128,221K shares. 
The put/call ratio of DGX is 1.09, indicating a bearish outlook.
What are Other Shareholders Doing?
Price T Rowe Associates holds 7,195K shares representing 6.43% ownership of the company. In its prior filing, the firm reported owning 5,984K shares , representing an increase of 16.82%. The firm increased its portfolio allocation in DGX by 17.35% over the last quarter.
Jpmorgan Chase holds 4,332K shares representing 3.87% ownership of the company. In its prior filing, the firm reported owning 3,770K shares , representing an increase of 12.97%. The firm increased its portfolio allocation in DGX by 9.24% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 3,593K shares representing 3.21% ownership of the company. In its prior filing, the firm reported owning 3,502K shares , representing an increase of 2.52%. The firm decreased its portfolio allocation in DGX by 2.83% over the last quarter.
VFINX - Vanguard 500 Index Fund Investor Shares holds 3,169K shares representing 2.83% ownership of the company. In its prior filing, the firm reported owning 3,085K shares , representing an increase of 2.65%. The firm decreased its portfolio allocation in DGX by 3.12% over the last quarter.
Boston Partners holds 3,040K shares representing 2.72% ownership of the company. In its prior filing, the firm reported owning 2,296K shares , representing an increase of 24.48%. The firm increased its portfolio allocation in DGX by 28.82% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
